Catalent Pharma Solutions Announces First FDA Product Approval for Brussels Syringe Facility

Catalent Pharma Solutions, Inc., one of the leading providers of advanced technologies and outsourced services to the global pharmaceutical, biotechnology and consumer health industry, has received notice that the United States Food and Drug Administration has approved the sale of a prescription product manufactured in Catalent´s recently opened, state–of–the–art pre–filled syringe facility in Brussels, Belgium. Syringes from Catalent´s Brussels facility will likely be dispensed to patients in the United States in upcoming months.

Richard Yarwood, group president of Catalent´s Sterile Technologies segment, said, "We are very pleased to have reached this important milestone in the evolution of our Brussels facility, and to further extend our strategic partnership with this customer. With this first FDA product approval, we even more strongly positioned to help our customers satisfy the fast growing U.S. market demand for drugs and biologics in prefilled syringe format."

Forward–Looking Statements

This release contains forward–looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward–looking statements generally can be identified by the use of statements that include phrases such as "believe," "expect," "anticipate", "intend", "estimate", "plan", "project", "foresee", "likely", "may", "will", "would" or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward–looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent´s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption "Risk Factors" in our most recent Annual Report on Form 10K, as filed with the Securities and Exchange Commission on September 29, 2008. All forward–looking statements speak only as of the date of this release or as of the date they are made, and Catalent Pharma Solutions does not undertake to update any forward– looking statements as a result of new information or future events or developments unless required by law.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is one of the leading providers of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at more than 30 facilities worldwide and generates more than $1.8 billion of annual revenue. For more information, visit www.catalent.com.